P38 Mapk Inhibitors For Neurodegenerative Diseases is a treatment approach for neurodegenerative diseases. This page provides comprehensive information about its mechanism of action, clinical evidence, and therapeutic potential.
The p38 mitogen-activated protein kinase (MAPK) pathway has emerged as a critical therapeutic target for neurodegenerative diseases due to its central role in neuroinflammation, tau pathology, and neuronal death. p38 MAPK inhibitors represent one of the most advanced approaches for directly modulating the inflammatory component of neurodegeneration.
Key aspects of p38 MAPK inhibition therapy include:
This page covers the biology of p38 MAPK isoforms, the rationale for inhibition in neurodegeneration, clinical trial results, and the challenges that have limited therapeutic success.
p38 MAPK is activated by cellular stress and inflammatory cytokines:
Activated p38α phosphorylates:
| Compound | Company | Status | Indication |
|---|---|---|---|
| Losmapimod | Fulcrum Therapeutics | Phase 3 (FSHD) | Not approved for neurodegeneration |
| PH-797804 | Pfizer | Discontinued | COPD |
| Pamapimod | Roche | Discontinued | Rheumatoid arthritis |
| VX-745 | Vertex | Discontinued | Rheumatoid arthritis |
The study of P38 Mapk Inhibitors For Neurodegenerative Diseases has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Sun A, Liu M, Nguyen XV, Bing G. p38 MAP kinase is activated in Alzheimer's disease brain. J Alzheimers Dis. 2003;5(2):87-95. ↩︎
Roy SM, Grum-Tokars VL, Schavocky JP, et al. Targeting human central nervous system node kinases and the p38 pathway for Alzheimer's disease. Neurochem Res. 2015;40(10):2046-2057. ↩︎
Karunaratne T, Calcines C, Natarajan C, et al. p38 MAPK in neurodegeneration: a therapeutic target? Expert Opin Ther Targets. 2020;24(5):425-438. ↩︎